Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
137 Results for "
hdac8
" in MedChemExpress (MCE) Product Catalog:
Products (137)
137 Results for "hdac8" in MCE Product Catalog:
AES-350 is a potent and orally active HDAC6 inhibitor with an IC50 and a Ki of 0.0244 μM and 0.035 μM, respectively. AES-350 is also against HDAC3, HDAC8 in an enzymatic activity assay with IC50 values of 0.187 μM and 0.245 μM, respectively. AES-350 triggers apoptosis in AML cells through HDAC inhibition and can be used for acute myeloid leukemia (AML) research .
Cat. No.: HY-144293
CAS No.: 1916505-13-9
HDAC-IN-31 is a potent, selective and orally active HDAC inhibitor with IC50s of 84.90, 168.0, 442.7, >10000 nM for HDAC1, HDAC2, HDAC3, HDAC8, respectively. HDAC-IN-31 induces apoptosis and cell cycle arrests at G2/M phase. HDAC-IN-31 shows good antitumor efficacy. HDAC-IN-31 has the potential for the research of diffuse large B-cell lymphoma .
Cat. No.: HY-117093
CAS No.: 423731-10-6
H8-A5 is a novel human histone deacetylase 8 (HDAC8) inhibitor. A highly specific ZBG-based pharmacophore model was developed by incorporating a custom zinc-binding group (ZBG) feature. Pharmacophore-based virtual screening identified three novel HDAC8 inhibitors with low micromolar IC50 values (1.8-1.9 μM). Further studies showed that H8-A5 was more selective for HDAC8 than HDAC1/4 and exhibited antiproliferative activity in MDA-MB-231 cancer cells. Molecular docking and molecular dynamics studies showed that H8-A5 could bind to HDAC8, providing a good starting point for the development of HDAC8 inhibitors for cancer treatment.
Cat. No.: HY-119550
CAS No.: 383892-69-1
J1075 is a selective Schistosoma mansoni HDAC8 inhibitor (with decreased affinity for human HDAC8). J1075 can induce apoptosis (Apoptosis) and death in schistosome cells. J1075 holds research value in the field of anti-parasitic agents .
Cat. No.: HY-119586
CAS No.: 233268-77-4
J1075 is a selective Schistosoma mansoni HDAC8 modulator (with decreased affinity for human HDAC8). J1075 can induce apoptosis (Apoptosis) and death in schistosome cells. J1075 holds research value in the field of anti-parasitic agents .
Cat. No.: HY-126829
CAS No.: 1260635-77-5
Coumarin-SAHA is a fluorescent probe for determining the binding affinities (kd) and the dissociation off-rates (koff) of the HDAC8-inhibitor complexes .
Cat. No.: HY-111342R
CAS No.: 1417997-93-3
Target:
Research Areas:
HDAC8-IN-1 (Standard) is the analytical standard of HDAC8-IN-1 (HY-111342). This product is intended for research and analytical applications. HDAC8-IN-1 is a HDAC8 inhibitor with an IC50 of 27.2 nM.
Cat. No.: HY-181979
Research Areas:
HDAC8-IN-15 is a selective HDAC8 inhibitor with an IC50 of 0.40 μM. HDAC8-IN-15 increases the acetylation level of the HDAC8 substrate SMC3 without altering the total protein level of SMC3. HDAC8-IN-15 reduces cancer cell viability, inhibits colony formation, slows cell migration, induces apoptosis, and causes cell cycle arrest at the SubG1 phase. HDAC8-IN-15 can be used in studies related to neuroblastoma .
Cat. No.: HY-111027
CAS No.: 949792-00-1
HDAC8-IN-13 is a novel histone deacetylase 8 (HDAC8) inhibitor with antiparasitic activity. HDAC8-IN-13 can effectively inhibit the acetyl-L-lysine deacetylase activity of schistosomes, affecting the parasite's infectivity. HDAC8-IN-13 can induce apoptosis and cause the death of schistosome cells. Through a specific structural basis design, HDAC8-IN-13 exhibits reduced affinity for human HDACs, thereby enhancing its selectivity .
Cat. No.: HY-182035
CAS No.: 2464465-06-1
HDAC8-IN-16 is a selective histone deacetylase 8 (HDAC8) inhibitor with an IC50 of 0.16 μM. HDAC8-IN-16 induces cell apoptosis, triggers G2/M phase cell cycle arrest, and moderately inhibits cancer cell proliferation. HDAC8-IN-16 is applicable to relevant research on colorectal cancer .
Cat. No.: HY-187382
HDAC8-IN-17 is a histone deacetylase 8 inhibitor with human IC50 values of 0.08 μM, 0.44 μM, and 1.9 μM, and high selectivity over HDAC1, HDAC2, HDAC3, and HDAC6. HDAC8-IN-17 exhibits slow-binding, reversible uncompetitive inhibition via allosteric binding to the enzyme-substrate complex. HDAC8-IN-17 induces selective hyperacetylation of SMC3. HDAC8-IN-17 can be used for the research of cancer .
Cat. No.: HY-P702858
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: hdac8; RPD3; Prev. hdacL1; Histone Deacetylase-Like 1; Prev. MRXS6; Wilson-Turner X-Linked Mental Retardation Syndrome; Prev. WTS; Histone Deacetylase; Protein Decrotonylase hdac8; CDA07; Protein Deacetylase hdac8; CDLS5; KDAC8; Histone Deacetylase 8; HD8
Species:
Human
Source:
Sf9 insect cells
Cat. No.: HY-150772
CAS No.: 2413587-26-3
Research Areas:
Tubulin/HDAC-IN-1 is a dual tubulin and HDAC-IN-1 inhibitor through CH/π interaction with tubulin and hydrogen bond interaction with HDAC8. Tubulin/HDAC-IN-1 inhibits tubulin polymerization and selectively inhibits HDAC8 (IC50: 150 nM). Tubulin/HDAC-IN-1 has cytotoxicity against various human cancer cells, also arrests cell cycle in the G2/M phase and induces cell apoptosis. Tubulin/HDAC-IN-1 can be used in the research of hematologic and solid tumors such as neuroblastoma, leukemia .
Cat. No.: HY-P75144
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: hdac8; RPD3; Prev. hdacL1; Histone Deacetylase-Like 1; Prev. MRXS6; Wilson-Turner X-Linked Mental Retardation Syndrome; Prev. WTS; Histone Deacetylase; Protein Decrotonylase hdac8; CDA07; Protein Deacetylase hdac8; CDLS5; KDAC8; Histone Deacetylase 8; HD8
Species:
Mouse
Source:
Sf9 insect cells
Cat. No.: HY-189297
Target:
Research Areas:
HDAC8/PIM1-IN-1 is a synthetic multi-target-directed ligand (MTDL) derived from 2-ureido-6-nitrobenzamide, and computational simulations predict it to be a dual-target inhibitor of HDAC8 and PIM1. HDAC8/PIM1-IN-1 holds potential for applications in research related to cancer and neurodegenerative diseases .
Cat. No.: HY-112908
CAS No.: 2285346-31-6
Target:
Research Areas:
RTS-V5 is a dual HDAC/proteasome inhibitor with IC50s of 6.9, 18, 15, 0.27, 0.53 μM for HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, respectively.
Cat. No.: HY-151248
CAS No.: 2919691-32-8
Target:
Research Areas:
HDAC2-IN-1 (Compound 17) is a brain penetrant, orally active, competitive HDAC2 inhibitor with an IC50 of 0.5 μM . HDAC2-IN-1 also inhibits HDAC1 and HDAC8 with IC50s of 1.61 μM and 0.98 μM, respectively .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
